Russell Gardner Witt

Dr. Russell Gardner Witt


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MFMichela Frascoli
Michela Frascoli
LCLacy Coniglio
Lacy Coniglio
Russell Gardner WittRussell Gardner Witt
Russell Gardner Witt
CJCerine Jeanty
Cerine Jeanty
SFShannon Fleck-Derderian
Shannon Fleck-Derderian
TMTippi C. MacKenzie
Tippi C. MacKenzie
Human fetal T cell activation against maternal antigens could promote uterine contractions in preterm labor.

26 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
QNQuoc-Hung Nguyen
Quoc-Hung Nguyen
Russell Gardner WittRussell Gardner Witt
Russell Gardner Witt
BWBowen Wang
Bowen Wang
CECarlo Eikani
Carlo Eikani
JSJeremy Shea
Jeremy Shea
TMTippi C. MacKenzie
Tippi C. MacKenzie
In utero therapy with recombinant enzyme or hematopoietic stem cells in MPS7 mice induces tolerance to missing enzyme and corrects brain microglia.

1 January 2022 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
Russell Gardner WittRussell Gardner Witt
Russell Gardner Witt
DEDerek J. Erstad
Derek J. Erstad
JWJennifer A. Wargo
Jennifer A. Wargo
The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite improvements in patient response rates and survival with these new treatments, there exists a large portion of patients with surgically resectable disease that are high risk for relapse. Patients with high-risk resectable melanoma account for up to 20% of newly diagnosed cases. For this high-risk group of patients, neoadjuvant therapy has many purposed advantages over adjuvant therapy, including a more robust immune response due to abundant tumor antigens at treatment initiation, the ability to assess pathologic response to therapy, tumor downstaging leading to increased disease resectability, and a potential decreased need for extensive lymphadenectomies. These findings have been backed by preclinical models and multiple neoadjuvant trials are underway. In this review, we will discuss the trials that have set the foundation for the current treatment standards and discuss the role and rationale for neoadjuvant therapy for high-risk malignant melanomas.

5 June 2024 in Hepatology
Verified
Journal Article
Open access
YZYunwei Zhang
Yunwei Zhang
CCChunyan Cao
Chunyan Cao
CLChaofan Li
Chaofan Li
Russell Gardner WittRussell Gardner Witt
Russell Gardner Witt
HHHai Huang
Hai Huang
HZHongji Zhang
Hongji Zhang
Liver diseases contribute to ~2 million deaths each year and account for 4% of all deaths globally. Despite various treatment options, the management of liver diseases remains challenging. Physical exercise is a promising nonpharmacological approach to maintain and restore homeostasis and effectively prevent and mitigate liver diseases. In this review, we delve into the mechanisms of physical exercise in preventing and treating liver diseases, highlighting its effects on improving insulin sensitivity, regulating lipid homeostasis, and modulating immune function. In addition, we evaluate the impact of physical exercise on various liver diseases, including liver ischemia/reperfusion injury, cardiogenic liver disease, metabolic dysfunction–associated steatotic liver disease, portal hypertension, cirrhosis, and liver cancer. In conclusion, the review underscores the effectiveness of physical exercise as a beneficial intervention in combating liver diseases.

15 April 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Russell Gardner WittRussell Gardner Witt
Russell Gardner Witt
LBLily Blair
Lily Blair
MFMichela Frascoli
Michela Frascoli
MRMichael J. Rosen
Michael J. Rosen
QNQuoc-Hung Nguyen
Quoc-Hung Nguyen
TMTippi C. Mackenzie
Tippi C. Mackenzie
Chorioamnionitis has been linked to spontaneous preterm labor and complications such as neonatal sepsis. We hypothesized that microbial cell-free (cf) DNA would be detectable in maternal plasma in patients with chorioamnionitis and could be the basis for a non-invasive method to detect fetal exposure to microorganisms. The purpose of this study was to determine whether next generation sequencing could detect microbial cfDNA in maternal plasma in patients with chorioamnionitis. Maternal plasma (n = 94) and umbilical cord plasma (n = 120) were collected during delivery at gestational age 28–41 weeks. cfDNA was extracted and sequenced. Umbilical cord plasma samples with evidence of contamination were excluded. The prevalence of microorganisms previously implicated in choriomanionitis, neonatal sepsis and intra-amniotic infections, as described in the literature, were examined to determine if there was enrichment of these microorganisms in this cohort. Specific microbial cfDNA associated with chorioamnionitis was first detected in umbilical cord plasma and confirmed in the matched maternal plasma samples (n = 77 matched pairs) among 14 cases of histologically confirmed chorioamnionitis and one case of clinical chorioamnionitis; 63 paired samples were used as controls. A correlation of rank of a given microorganism across maternal plasma and matched umbilical cord plasma was used to assess whether signals found in umbilical cord plasma were also present in maternal plasma. Microbial DNA sequences associated with clinical and/or histological chorioamnionitis were enriched in maternal plasma in cases with suspected chorioamnionitis when compared to controls (12/14 microorganisms, p = 0.02). Analysis of the microbial cfDNA in umbilical cord plasma among the 1,251 microorganisms detectable with this assay identified Streptococcus mitis, Ureaplasma spp., and Mycoplasma spp. in cases of suspected chorioamnionitis. This assay also detected cfDNA from Lactobacillus spp. in controls. Comparison between maternal plasma and umbilical cord plasma confirmed these signatures were also present in maternal plasma. Unbiased analysis of microorganisms with significantly correlated signal between matched maternal plasma and umbilical cord plasma identified the above listed 3 microorganisms, all of which have previously been implicated in patients with chorioamnionitis (Mycoplasma hominis p = 0.0001; Ureaplasma parvum p = 0.002; Streptococcus mitis p = 0.007). These data show that the pathogen signal relevant for chorioamnionitis can be identified in both maternal and umbilical cord plasma. This is the first report showing the detection of relevant microbial cell-free cfDNA in maternal plasma and umbilical cord plasma in patients with clinical and/or histological chorioamnionitis. These results may lead to the development of a specific assay to detect perinatal infections for targeted therapy to reduce early neonatal sepsis complications.

15 July 2022 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
Russell Gardner WittRussell Gardner Witt
Russell Gardner Witt
YHYuki Hirata
Yuki Hirata
LPLaura R. Prakash
Laura R. Prakash
TNTimothy E. Newhook
Timothy E. Newhook
JMJessica E. Maxwell
Jessica E. Maxwell
NINaruhiko Ikoma
Naruhiko Ikoma